The spectrum of thyroid function tests during hospitalization for SARS COV-2 infection.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
May 2021
Historique:
received: 04 12 2020
accepted: 05 03 2021
pubmed: 9 3 2021
medline: 15 4 2021
entrez: 8 3 2021
Statut: ppublish

Résumé

Alterations in thyroid function tests (TFTs) have been recorded during SARS-CoV-2 infection as associated to either a destructive thyroiditis or a non-thyroidal illness. We studied 144 consecutive COVID-19 patients admitted to a single center in intensive or subintensive care units. Those with previous thyroid dysfunctions or taking interfering drugs were excluded. Differently from previous reports, TSH, FT3, FT4, thyroglobulin (Tg), anti-Tg autoantibodies (TgAb) were measured at baseline and every 3-7 days. C-reacting protein (CRP), cortisol and IL-6 were also assayed. The majority of patients had a normal TSH at admission, usually with normal FT4 and FT3. Low TSH levels were found either at admission or during hospitalization in 39% of patients, associated with low FT3 in half of the cases. FT4 and Tg levels were normal, and TgAb-negative. TSH and FT3 were invariably restored at the time of discharge in survivors, whereas were permanently low in most deceased cases, but only FT3 levels were predictors of mortality. Cortisol, CRP and IL-6 levels were higher in patients with low TSH and FT3 levels. Almost half of our COVID-19 patients without interfering drugs had normal TFTs both at admission and during follow-up. In this series, the transient finding of low TSH with normal FT4 and low FT3 levels, inversely correlated with CRP, cortisol and IL-6 and associated with normal Tg levels, is likely due to the cytokine storm induced by SARS-Cov-2 with a direct or mediated impact on TSH secretion and deiodinase activity, and likely not to a destructive thyroiditis.

Identifiants

pubmed: 33683214
doi: 10.1530/EJE-20-1391
pii: EJE-20-1391
pmc: PMC9494333
doi:
pii:

Substances chimiques

Autoantibodies 0
Interleukin-6 0
Triiodothyronine 06LU7C9H1V
Thyrotropin 9002-71-5
C-Reactive Protein 9007-41-4
Thyroglobulin 9010-34-8
Thyroxine Q51BO43MG4
Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

699-709

Références

J Endocrinol Invest. 2020 Aug;43(8):1171-1172
pubmed: 32488726
Metabolism. 1998 Oct;47(10):1289-93
pubmed: 9781636
J Clin Endocrinol Metab. 2020 Jun 1;105(6):
pubmed: 31996918
J Endocrinol. 2004 Aug;182(2):315-23
pubmed: 15283692
BMJ Case Rep. 2020 Aug 25;13(8):
pubmed: 32843467
Cytokine. 2021 Jan;137:155302
pubmed: 33002740
Clin Endocrinol (Oxf). 2005 Aug;63(2):197-202
pubmed: 16060914
Emerg Med Pract. 2020 Apr 16;22(5 Suppl):CD1-CD2
pubmed: 32297727
J Endocrinol Invest. 2020 Aug;43(8):1173-1174
pubmed: 32504458
Cytokine Growth Factor Rev. 2020 Jun;53:25-32
pubmed: 32446778
Eur J Endocrinol. 2020 Oct;183(4):381-387
pubmed: 32698147
J Clin Endocrinol Metab. 2020 Jul 1;105(7):
pubmed: 32436948
J Endocrinol. 2010 Apr;205(1):1-13
pubmed: 20016054
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
Eur J Endocrinol. 2004 Oct;151(4):497-502
pubmed: 15476451
J Endocrinol Invest. 2021 May;44(5):1085-1090
pubmed: 33025553
Case Rep Endocrinol. 2020 Sep 28;2020:8891539
pubmed: 33005461
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e926-e935
pubmed: 33141191
Biochem Cell Biol. 2010 Aug;88(4):723-30
pubmed: 20651845
Thyroid. 2021 Jan;31(1):8-11
pubmed: 32600165
J Clin Endocrinol Metab. 2020 Oct 1;105(10):
pubmed: 32780854
Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741
pubmed: 32738929
Endocrinology. 2021 Mar 1;162(3):
pubmed: 33543236
Hormones (Athens). 2021 Mar;20(1):219-221
pubmed: 32676935
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e803-e811
pubmed: 33180932
J Endocrinol Invest. 2021 May;44(5):891-904
pubmed: 33559848
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Thyroid. 2016 Oct;26(10):1343-1421
pubmed: 27521067
J Endocrinol Invest. 2021 May;44(5):1031-1040
pubmed: 33140379
Infect Dis Poverty. 2020 Apr 28;9(1):45
pubmed: 32345362
Hum Pathol. 2007 Jan;38(1):95-102
pubmed: 16996569

Auteurs

Irene Campi (I)

Division of Endocrine and Metabolic Diseases and Laboratory of Endocrine and Metabolic Research, Istituto Auxologico Italiano, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

Ilaria Bulgarelli (I)

Laboratorio Analisi Cliniche, Centro di Ricerche e Tecnologie Biomediche, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Antonella Dubini (A)

Laboratorio Analisi Cliniche, Centro di Ricerche e Tecnologie Biomediche, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Giovanni Battista Perego (GB)

Department of Cardiovascular Neural and Metabolic Sciences, Istituto Auxologico Italiano, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), San Luca Hospital, Milan, Italy.

Elena Tortorici (E)

Department of Cardiovascular Neural and Metabolic Sciences, Istituto Auxologico Italiano, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), San Luca Hospital, Milan, Italy.

Camilla Torlasco (C)

Department of Cardiovascular Neural and Metabolic Sciences, Istituto Auxologico Italiano, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), San Luca Hospital, Milan, Italy.

Erminio Torresani (E)

Laboratorio Analisi Cliniche, Centro di Ricerche e Tecnologie Biomediche, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Lorenzo Rocco (L)

Division of Endocrine and Metabolic Diseases and Laboratory of Endocrine and Metabolic Research, Istituto Auxologico Italiano, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.

Luca Persani (L)

Division of Endocrine and Metabolic Diseases and Laboratory of Endocrine and Metabolic Research, Istituto Auxologico Italiano, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.

Laura Fugazzola (L)

Division of Endocrine and Metabolic Diseases and Laboratory of Endocrine and Metabolic Research, Istituto Auxologico Italiano, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH